Bone Biologics CORP 8-K filings

Bone Biologics Corporation provided a mid-year update highlighting progress in its NB1 clinical development, manufacturing readiness, and intellectual property initiatives, supported by a recent $3.0 million financing.

Bone Biologics Corporation has postponed its 2026 annual meeting of stockholders to September 28, 2026, to include an additional proposal for stockholder consideration.

Bone Biologics Corporation announced the pricing of a private placement of common stock (or pre-funded warrants) and Series F and G warrants, raising approximately $3.0 million in upfront capital.

Bone Biologics Corporation announced a new prospectus supplement for an at-the-market offering to sell up to $1.064 million of common stock.

Bone Biologics Corporation summarized its 2025 operational, scientific, and corporate achievements and outlined its strategic plans for 2026.

Bone Biologics CEO Jeffrey Frelick issued a letter to stockholders detailing progress on NB1, clinical study milestones, and financial runway.

Bone Biologics Corporation has successfully priced and closed a public offering raising $5.0 million in gross proceeds, including common stock and various warrants, to fund clinical trials and expand its patent portfolio.

Bone Biologics Corporation announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Bone Biologics Corporation has announced a 1-for-6 reverse stock split of its common stock, effective June 10, 2025, aiming to consolidate shares and potentially address Nasdaq listing requirements.

Bone Biologics Corporation's stockholders approved a reverse stock split, a substantial increase in shares reserved for its equity incentive plan, and re-elected its board of directors at its annual meeting.

Bone Biologics Corporation received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

Bone Biologics Corporation announces the date for its 2025 Annual Meeting of Stockholders and adjusts deadlines for shareholder proposals and director nominations.

Bone Biologics Corporation has updated its prospectus supplement to increase the maximum amount of shares it can sell under its At The Market Offering Agreement to $832,009.

Bone Biologics has appointed Phillip Meikle, a seasoned orthopedic executive, to its board of directors, replacing Don Hankey who retired after seven years of service.

Bone Biologics Corporation reported the immediate resignation of director Don Hankey, effective October 1, 2024.

Bone Biologics Corporation has entered into an agreement with H.C. Wainwright & Co., LLC to sell up to $1,143,121 of its common stock through an at-the-market offering program.

Bone Biologics Corporation held its annual stockholder meeting on September 17, 2024, where stockholders elected directors, approved executive compensation on an advisory basis, and ratified the appointment of an independent accounting firm.

Bone Biologics Corporation has entered into an agreement for the exercise of existing warrants, generating approximately $2.1 million in gross proceeds and issuing new warrants.

Bone Biologics has announced the treatment of the first two patients in its pilot clinical study of the NB1 bone graft device for spine fusion.

Bone Biologics Corporation has amended agreements with its CEO and CFO, including potential transaction bonuses upon acquisition.

Bone Biologics Corporation has successfully priced and closed a public offering, raising approximately $2 million through the sale of common stock and warrants.

Bone Biologics Corporation reports progress in its NB1 clinical program, with three hospital sites engaged for a pilot trial evaluating the safety and effectiveness of NB1 in spinal fusion.

Bone Biologics Corporation has reached a settlement agreement to resolve a breach of contract lawsuit, agreeing to pay $750,000 to the plaintiffs.

Bone Biologics Corporation has appointed Robert E. Gagnon, a seasoned finance executive, to its Board of Directors, effective immediately.